MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
4.130
+0.240 (6.17%)
At close: Jul 24, 2026, 4:00 PM EDT
4.130
0.00 (0.00%)
After-hours: Jul 24, 2026, 5:40 PM EDT
MannKind Employees
As of December 31, 2025, MannKind had 592 total employees, including 591 full-time and 1 part-time employees. The number of employees increased by 185 or 45.45% compared to the previous year.
Employees
592
Change (1Y)
185
Growth (1Y)
45.45%
Revenue / Employee
$609,431
Profits / Employee
-$40,395
Market Cap
1.28B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 592 | 185 | 45.45% | 591 | 1 |
| Dec 31, 2024 | 407 | -7 | -1.69% | 403 | 4 |
| Dec 31, 2023 | 414 | 19 | 4.81% | 411 | 3 |
| Dec 31, 2022 | 395 | 46 | 13.18% | 391 | 4 |
| Dec 31, 2021 | 349 | 108 | 44.81% | 348 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immatics | 678 |
| Ardelyx | 489 |
| MeiraGTx Holdings | 409 |
| Capricor Therapeutics | 231 |
| Alpha Tau Medical | 121 |
| Inhibrx Biosciences | 110 |
| ORIC Pharmaceuticals | 104 |
MNKD News
- 8 hours ago - MannKind Transcript: FDA announcement - Transcripts
- 8 hours ago - MannKind Press release: FDA announcement - Filings
- 11 hours ago - MannKind announces FDA approval of Furoscix ReadyFlow - TheFly
- 11 hours ago - MannKind announces $50M private placement - TheFly
- 11 hours ago - MannKind Announces $50 Million Private Placement - GlobeNewsWire
- 11 hours ago - MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - GlobeNewsWire
- 1 day ago - MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright - TheFly
- 4 weeks ago - MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D - GlobeNewsWire